GM
Therapeutic Areas
Scynexis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BREXAFEMME® (ibrexafungerp) | Vulvovaginal Candidiasis (VVC) and Recurrent VVC (rVVC) | Approved |
| Ibrexafungerp (SCY-078) | Invasive Candidiasis / Invasive Fungal Infections | Phase 3 |
| SCY-247 | Invasive Fungal Infections (drug-resistant) | Phase 1 |
| PXL-770 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2-ready |
Leadership Team at Scynexis
DA
David Angulo, M.D.
President and Chief Executive Officer
IM
Ivor Macleod, MBA, CPA
Chief Financial Officer
SS
Scott Sukenick
Chief Legal Officer
DG
Daniella Gigante
Vice President, Human Resources and Information Technology
RF
Rossana Ferrara-Pontoriero, Ph.D.
Vice President, Business Development and Alliance Management
AA
Armando Anido
Director
SC
Steven C. Gilman, Ph.D.
Director
AF
Ann F. Hanham, Ph.D.
Director
DH
David Hastings
Director
PT
Philippe Tinmouth
Director